Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support the discovery and development of novel natural products that are safe, non-toxic, and efficacious for cancer interception and prevention. The UG3 phase will provide up to three years of support for milestone-driven initial target selection, verification of the target in clinical samples and preclinical in vivo studies, assay development, and/or assay validation for target activity, as well as on-target toxicity screening, and pilot screening of natural agents. If UG3 milestones are met, support may be provided for a full-scale screening, identification of active natural compounds, full-scale evaluation of screened individual agents, assessment of the natural product’s effect in vitro and in vivo, and determining the optimal dose for subsequent studies and safety testing in the UH3 phase.